9200 ORAL A Phase 3 Study Comparing Melphalan-Prednisone-Lenalidomide (MPR) With High-dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Patients With Multiple Myeloma (MM)
暂无分享,去创建一个
M. Boccadoro | A. Nagler | D. B. Yehuda | F. Cavallo | F. Raimondo | A. Palumbo | P. Corradini | S. Grammatico | T. C. D. Toritto | P. Omedè